Literature DB >> 35786977

LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients.

Akif Altinbas1, Jacinta A Holmes1, Shadi Salloum1, Anna Lidofsky1, Nadia Alatrakchi1, Ma Somsouk2, Peter Hunt2, Steven Deeks2, Kara W Chew3, Georg Lauer1, Annie Kruger1, Wenyu Lin1, Raymond T Chung1.   

Abstract

Background: Lysil oxidase like enzyme-2 (LOXL-2) and TNC-C play important roles in organ fibrosis. We assessed circulating LOXL-2 and TNC-C levels and their relationship to fibrosis severity in HIV- and/or HCV-infected individuals.
Methods: Healthy controls (n = 22), HIV mono- (n = 15), HCV mono- (n = 52) and HCV/HIV-co-infected (n = 92) subjects were included.
Results: LOXL-2 and TNC-C levels were significantly higher in HCV mono- and HCV/HIV-co-infected individuals with F0 compared to healthy controls. In addition, in HCV/HIV-co-infected individuals, LOXL-2 levels were higher in intermediate fibrosis compared to no/mild fibrosis.
Conclusion: In HCV/HIV-co-infected study participants, both LOXL-2 and TNC-C were significantly higher in intermediate fibrosis compared to no/mild fibrosis, but did not further increase with advanced fibrosis. Furthermore, both markers were elevated among HCV/HIV-positive individuals with mild/no fibrosis.

Entities:  

Keywords:  HIV infection; LOXL-2; TNC-C; antiretroviral therapy; hepatitis C virus infection; liver fibrosis; peginterferon and ribavirin therapy

Mesh:

Substances:

Year:  2022        PMID: 35786977      PMCID: PMC9437769          DOI: 10.2217/bmm-2021-0596

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.498


  28 in total

1.  Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice.

Authors:  A El-Karef; T Yoshida; E C Gabazza; T Nishioka; H Inada; T Sakakura; K Imanaka-Yoshida
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

2.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

3.  Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization.

Authors:  Taizo Kimura; Kazuko Tajiri; Akira Sato; Satoshi Sakai; Zheng Wang; Toshimichi Yoshida; Toshimitsu Uede; Michiaki Hiroe; Kazutaka Aonuma; Masaki Ieda; Kyoko Imanaka-Yoshida
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

4.  Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey.

Authors:  Onur Baser; Akif Altinbas; Erdem Baser; M Furaha Kariburyo
Journal:  Value Health Reg Issues       Date:  2015-10-02

5.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

6.  Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Authors:  Stephen A Harrison; Manal F Abdelmalek; Stephen Caldwell; Mitchell L Shiffman; Anna Mae Diehl; Reem Ghalib; Eric J Lawitz; Don C Rockey; Raul Aguilar Schall; Catherine Jia; Bryan J McColgan; John G McHutchison; G Mani Subramanian; Robert P Myers; Zobair Younossi; Vlad Ratziu; Andrew J Muir; Nezam H Afdhal; Zachary Goodman; Jaime Bosch; Arun J Sanyal
Journal:  Gastroenterology       Date:  2018-07-07       Impact factor: 22.682

7.  HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB.

Authors:  Wenyu Lin; Guoyang Wu; Shaoyong Li; Ethan M Weinberg; Kattareeya Kumthip; Lee F Peng; Jorge Méndez-Navarro; Wen-Chi Chen; Nikolaus Jilg; Hong Zhao; Kaku Goto; Leiliang Zhang; Mark A Brockman; Detlef Schuppan; Raymond T Chung
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

8.  Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy.

Authors:  Angela Puente; Jose Ignacio Fortea; Miguel Posadas; Agustin Garcia Blanco; Laura Rasines; Joaquin Cabezas; Maria Teresa Arias Loste; Susana Llerena; Paula Iruzubieta; Emilio Fábrega; Javier Crespo
Journal:  J Clin Med       Date:  2019-08-17       Impact factor: 4.241

9.  Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma.

Authors:  Andromachi Kotsafti; Fabio Farinati; Romilda Cardin; Umberto Cillo; Donato Nitti; Marina Bortolami
Journal:  BMC Gastroenterol       Date:  2012-08-28       Impact factor: 3.067

10.  LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.

Authors:  Mordehay Klepfish; Tamar Gross; Milena Vugman; Nikolaos A Afratis; Sapir Havusha-Laufer; Eli Brazowski; Inna Solomonov; Chen Varol; Irit Sagi
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.